1. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13:321-335.PMID:
23618829.
2. Kamada N, Núñez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014;146:1477-1488.PMID:
24503128.
3. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013;14:685-690.PMID:
23778796.
4. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous
Clostridium species. Science 2011;331:337-341.PMID:
21205640.
5. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 1997;41:245-251.PMID:
9301506.
6. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446-450.PMID:
24226770.
7. Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2013;3:14-24.PMID:
25437605.
8. Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2015;12:77-87.PMID:
25385227.
9. Rautava S, Luoto R, Salminen S, Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. Nat Rev Gastroenterol Hepatol 2012;9:565-576.PMID:
22890113.
10. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205-217.PMID:
25732745.
11. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012;9:599-608.PMID:
22907164.
12. Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010;8:564-577.PMID:
20622892.
13. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007;104:13780-13785.PMID:
17699621.
15. Wright DP, Rosendale DI, Robertson AM. Prevotella enzymes involved in mucin oligosaccharide degradation and evidence for a small operon of genes expressed during growth on mucin. FEMS Microbiol Lett 2000;190:73-79.PMID:
10981693.
16. Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of
Bacteroides and
Prevotella spp. in ulcerative colitis. J Med Microbiol 2006;55:617-624.PMID:
16585651.
17. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145:745-757.PMID:
21565393.
18. Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013;123:700-711.PMID:
23281400.
19. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231.PMID:
9784526.
20. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-261.PMID:
8402910.
21. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005;128:891-906.PMID:
15825073.
22. Bohn E, Bechtold O, Zahir N, et al. Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. Inflamm Bowel Dis 2006;12:853-862.PMID:
16954804.
23. Kim SC, Tonkonogy SL, Karrasch T, Jobin C, Sartor RB. Dualassociation of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis 2007;13:1457-1466.PMID:
17763473.
24. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67:2969-2974.PMID:
10338507.
25. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012;4:1095-1119.PMID:
23016134.
26. DeVoss J, Diehl L. Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease. Toxicol Pathol 2014;42:99-110.PMID:
24231829.
27. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in
Il10-/- mice. Nature 2012;487:104-108.PMID:
22722865.
28. Muyzer G, Stams AJ. The ecology and biotechnology of sulphate-reducing bacteria. Nat Rev Microbiol 2008;6:441-454.PMID:
18461075.
29. Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O'Connell PR. Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum 2010;53:1530-1536.PMID:
20940602.
31. Hentges DJ, Maier BR, Burton GC, Flynn MA, Tsutakawa RK. Effect of a high-beef diet on the fecal bacterial flora of humans. Cancer Res 1977;37:568-571.PMID:
832279.
32. Palm NW, de Zoete MR, Cullen TW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014;158:1000-1010.PMID:
25171403.
33. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-1471.PMID:
17120402.
34. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481-496.PMID:
15157822.
35. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79PMID:
10.1186/gb-2012-13-9-r79. PMID:
23013615.
36. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010;105:2687-2692.PMID:
20940708.
37. Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012;130:e794-e803.PMID:
23008454.
38. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775-778.PMID:
15256979.
39. Schubert AM, Sinani H, Schloss PD. Antibiotic-Induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against
Clostridium difficile. MBio 2015;6:e00974-e00915.PMID:
10.1128/mBio.00974-15. PMID:
26173701.
40. Rupnik M, Wilcox MH, Gerding DN.
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-536.PMID:
19528959.
41. Musa S, Thomson S, Cowan M, Rahman T.
Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol 2010;45:261-272.PMID:
20025557.
42. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of
Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-344.PMID:
17368233.
43. Issa M, Vijayapal A, Graham MB, et al. Impact of
Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-351.PMID:
17368234.
45. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibioticinduced shifts in the mouse gut microbiome and metabolome increase susceptibility to
Clostridium difficile infection. Nat Commun 2014;5:3114PMID:
10.1038/ncomms4114. PMID:
24445449.
46. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for
Clostridium difficile spores. J Bacteriol 2008;190:2505-2512.PMID:
18245298.
47. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to
Clostridium difficile. Nature 2015;517:205-208.PMID:
25337874.
48. Kruis W, Kalek HD, Stellaard F, Paumgartner G. Altered fecal bile acid pattern in patients with inflammatory bowel disease. Digestion 1986;35:189-198.PMID:
3817328.
49. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013;62:531-539.PMID:
22993202.
50. Cao Y, Shen J, Ran ZH. Association between
Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Gastroenterol Res Pract 2014;2014:872725PMID:
10.1155/2014/872725. PMID:
24799893.
51. Sokol H, Pigneur B, Watterlot L, et al.
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-16736.PMID:
18936492.
52. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.PMID:
15761078.
53. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011;343:d6617PMID:
10.1136/bmj.d6617. PMID:
22074852.
54. Akin H, Tözün N. Diet, microbiota, and colorectal cancer. J Clin Gastroenterol 2014;48(Suppl 1): S67-S69.PMID:
25291132.
55. Oostindjer M, Alexander J, Amdam GV, et al. The role of red and processed meat in colorectal cancer development: a perspective. Meat Sci 2014;97:583-596.PMID:
24769880.
57. Gill CI, Rowland IR. Diet and cancer: assessing the risk. Br J Nutr 2002;88(Suppl 1): S73-S87.PMID:
12215186.
58. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011;17:1519-1528.PMID:
21472114.
59. Sears CL.
Enterotoxigenic Bacteroides fragilis : a rogue among symbiotes. Clin Microbiol Rev 2009;22:349-369.PMID:
19366918.
60. Rhee KJ, Wu S, Wu X, et al. Induction of persistent colitis by a human commensal, enterotoxigenic
Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 2009;77:1708-1718.PMID:
19188353.
62. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of
Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006;12:782-786.PMID:
16842574.
63. Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayréde JP.
Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 2010;107:11537-11542.PMID:
20534522.
64. Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-123.PMID:
22903521.
65. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009;125:171-180.PMID:
19350627.
66. Vassallo G, Mirijello A, Ferrulli A, et al. Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther 2015;41:917-927.PMID:
25809237.
67. Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012;302:G966-G978.PMID:
22241860.
68. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53:96-105.PMID:
21254165.
69. Nistal E, Fernández-Fernández N, Vivas S, Olcoz JL. Factors Determining Colorectal Cancer: The Role of the Intestinal Microbiota. Front Oncol 2015;5:220PMID:
26528432.
70. Mueller S, Saunier K, Hanisch C, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006;72:1027-1033.PMID:
16461645.
71. Makivuokko H, Tiihonen K, Tynkkynen S, Paulin L, Rautonen N. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br J Nutr 2010;103:227-234.PMID:
19703328.
72. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010;5:e10667PMID:
10.1371/journal.pone.0010667. PMID:
20498852.
74. Kapatral V, Anderson I, Ivanova N, et al. Genome sequence and analysis of the oral bacterium Fusobacterium nucleatum strain ATCC 25586. J Bacteriol 2002;184:2005-2018.PMID:
11889109.
75. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW.
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.PMID:
23954158.
77. Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med 2010;42:530-538.PMID:
20868314.
78. Cenit MC, Olivares M, Codoñer-Franch P, Sanz Y. Intestinal microbiota and celiac disease: cause, consequence or coevolution? Nutrients 2015;7:6900-6923.PMID:
26287240.
79. Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 2011;11:219PMID:
10.1186/1471-2180-11-219. PMID:
21970810.
80. Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga ML, Sanz Y. Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol 2013;79:5472-5479.PMID:
23835180.
81. Wacklin P, Laurikka P, Lindfors K, et al. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol 2014;109:1933-1941.PMID:
25403367.
82. Combs MR. Lewis blood group system review. Immunohematology 2009;25:112-118.PMID:
20406017.
83. Parmar AS, Alakulppi N, Paavola-Sakki P, et al. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. Tissue Antigens 2012;80:488-493.PMID:
23075394.
85. Wacklin P, Tuimala J, Nikkilä J, et al. Faecal microbiota composition in adults is associated with the
FUT2 gene determining the secretor status. PLoS One 2014;9:e94863PMID:
24733310.
86. Lopez P, Gonzalez-Rodriguez I, Gueimonde M, Margolles A, Suarez A. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS One 2011;6:e24776PMID:
10.1371/journal.pone.0024776. PMID:
21966367.
87. Hurd EA, Domino SE. Increased susceptibility of secretor factor gene
Fut2-null mice to experimental vaginal candidiasis. Infect Immun 2004;72:4279-4281.PMID:
15213174.
88. Nieuwenhuizen WF, Pieters RH, Knippels LM, Jansen MC, Koppelman SJ. Is Candida albicans a trigger in the onset of coeliac disease? Lancet 2003;361:2152-2154.PMID:
12826451.
89. Mårild K, Ye W, Lebwohl B, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol 2013;13:109PMID:
10.1186/1471-230X-13-109. PMID:
23834758.
90. Galipeau HJ, McCarville JL, Huebener S, et al. Intestinal microbiota modulates gluten-induced immunopathology in humanized mice. Am J Pathol 2015;185:2969-2982.PMID:
26456581.
91. Akobeng AK, Ramanan AV, Buchan I, Heller RF. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child 2006;91:39-43.PMID:
16287899.
92. Peters U, Schneeweiss S, Trautwein EA, Erbersdobler HF. A case-control study of the effect of infant feeding on celiac disease. Ann Nutr Metab 2001;45:135-142.PMID:
11463995.
93. Fälth-Magnusson K, Franzen L, Jansson G, Laurin P, Stenhammar L. Infant feeding history shows distinct differences between Swedish celiac and reference children. Pediatr Allergy Immunol 1996;7:1-5.PMID:
8792377.
94. Olivares M, Albrecht S, De Palma G, et al. Human milk composition differs in healthy mothers and mothers with celiac disease. Eur J Nutr 2015;54:119-128.PMID:
24700375.
95. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.PMID:
16678561.
96. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014;11:497-505.PMID:
24751910.
97. Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49.PMID:
25446728.
98. Jeffery IB, O'Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61:997-1006.PMID:
22180058.
99. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013;25:e272-e282.PMID:
23433203.
100. Kim G, Deepinder F, Morales W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci 2012;57:3213-3218.PMID:
22573345.
101. Dridi B, Raoult D, Drancourt M. Archaea as emerging organisms in complex human microbiomes. Anaerobe 2011;17:56-63.PMID:
21420503.
102. DuPont AW. Postinfectious irritable bowel syndrome. Clin Infect Dis 2008;46:594-599.PMID:
18205536.
103. Connor BA. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005;41(Suppl 8): S577-S586.PMID:
16267722.
104. Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol 2014;20:3976-3985.PMID:
24744587.
105. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998;10:59-62.PMID:
9512954.
106. Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012;111:17-20.PMID:
22533211.
107. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 2011;23:473-480.PMID:
21856139.
108. de Roest RH, Dobbs BR, Chapman BA, et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract 2013;67:895-903.PMID:
23701141.
109. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015;64:93-100.PMID:
25016597.
110. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012;9:88-96.PMID:
22183182.
111. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent
Clostridium difficile. N Engl J Med 2013;368:407-415.PMID:
23323867.
112. Hourigan SK, Chen LA, Grigoryan Z, et al. Microbiome changes associated with sustained eradication of
Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther 2015;42:741-752.PMID:
26198180.
113. Kahouli I, Tomaro-Duchesneau C, Prakash S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol 2013;62:1107-1123.PMID:
23558140.
114. Gianotti L, Morelli L, Galbiati F, et al. A randomized doubleblind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol 2010;16:167-175.PMID:
20066735.
115. Ishikawa H, Akedo I, Otani T, et al. Randomized trial of dietary fiber and
Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005;116:762-767.PMID:
15828052.